Place de la Radiothérapie Interne Vectorisée dans l’arsenal thérapeutique des néoplasies neuroendocrines digestives

Latale Latale, Angèle Lafortune
(2026)

Files

LATALE_LATALE_ANGELE_LAFORTUNE_09312101_205-2026.pdf
  • UCLouvain restricted access
  • Adobe PDF
  • 6.72 MB

Details

Supervisors
Borbath, Ivan
Faculty
Faculté de pharmacie et des sciences biomédicales
Degree label
Master [60] en sciences biomédicales
Abstract
enBackground: Gastrointestinal neuroendocrine neoplasms are a group of rare and heterogeneous tumors whose incidence has increased over the years. This tumor heterogeneity is caused by factors such as grade, stage, location and the expression of somatostatin receptors on the surface of tumor cells. All of this makes management complex despite the various current therapeutic approaches. It was therefore important to introduce a more effective treatment that could be useful in cases of advanced or progressive tumors. PRRT (peptide receptor radionuclide therapy) was thus introduced since it allows targeting of somatostatin receptors using radioligands. Although this approach has been approved for its utility in treating these tumors, its therapeutic role among the other treatments in use remains to be determined. Methods: Major clinical trials such as NETTER-1, NETTER-2, COMPETE and OCLURANDOM were analyzed, followed by a retrospective analysis conducted on the behalf of patients treated by PRRT at Cliniques universitaires Saint-Luc. The retrospective analysis included 25 patients, and the data collected included demo-graphic information, treatment parameters and therapeutic response. These data were obtained from patients’ medical records. Results: the literature review demonstrates that treatment by PRRT is associated with improved progression-free survival (PFS) and better disease control. In the retrospective analysis, the median PFS of 22 months was consistent with that reported in the NETTER-1 study (22.8 months). Conclusion: compared with other treatments (targeted therapies and somatostatin analogs), PRRT has demonstrated a significant improvement in PFS for patients with metastatic, advanced and progressive gastrointestinal neuroendocrine tumors.